Gilead joins protein degradation drive with Nurix dealGilead has teamed up with protein degradation specialist Nurix on a project to find new cancer drugs, paying Share XGilead joins protein degradation drive with Nurix dealhttps://pharmaphorum.com/news/gilead-joins-protein-degradation-drive-with-nurix-deal/
Daiichi waits on FDA as AML drug quizartinib approved in JapanThe Japanese regulator has approved Daiichi Sankyo’s quizartinib for certain patients with acute myeloid leukaemia (AML), amid doubts Share XDaiichi waits on FDA as AML drug quizartinib approved in Japanhttps://pharmaphorum.com/news/daiichi-waits-on-fda-as-aml-drug-quizartinib-approved-in-japan/
Bayer’s regorafenib kicks off brain cancer platform trialBayer has become the first pharma company to take part in a new platform trial designed to find Share XBayer’s regorafenib kicks off brain cancer platform trialhttps://pharmaphorum.com/news/bayers-regorafenib-kicks-off-brain-cancer-platform-trial/
Merck & Co notches up another lung cancer use for KeytrudaBristol-Myers Squibb’s immunotherapy Opdivo has new competition in small cell lung cancer (SCLC) after the FDA approved its Share XMerck & Co notches up another lung cancer use for Keytrudahttps://pharmaphorum.com/news/merck-co-notches-up-another-lung-cancer-use-for-keytruda/
AZ sees triple approval in Japan for cancer and COPD drugsAstraZeneca has seen three of its drugs approved by the Japanese regulator – a new indication for its Share XAZ sees triple approval in Japan for cancer and COPD drugshttps://pharmaphorum.com/news/az-sees-triple-approval-in-japan-lynparza/
Japan approves Roche’s tumour agnostic cancer drug RozlytrekJapan has become the first country to approve Roche’s personalised cancer drug Rozlytrek (entrectinib). Roche added entrectinib to Share XJapan approves Roche’s tumour agnostic cancer drug Rozlytrekhttps://pharmaphorum.com/news/japan-approves-roches-tumour-agnostic-cancer-drug-rozlytrek/
As Lyrica patent expiry looms, Pfizer buys Array for $11.4bnPfizer has a made a $48 per share play for Array Biopharma, which values the cancer specialist at Share XAs Lyrica patent expiry looms, Pfizer buys Array for $11.4bnhttps://pharmaphorum.com/news/as-lyrica-patent-expiry-looms-pfizer-buys-array-for-11-4bn/
AZ prepares for showdown with AbbVie/J&J as Calquence shines in CLLAstraZeneca has announced data showing its cancer drug Calquence outperformed standard care in chronic lymphocytic leukaemia – reducing Share XAZ prepares for showdown with AbbVie/J&J as Calquence shines in CLLhttps://pharmaphorum.com/news/az-prepares-for-showdown-with-abbvie-jj-as-calquence-shines-in-cll/
FDA approves Herceptin biosimilar as US patent expiresThe FDA has approved Amgen and Allergan’s biosimilar of Roche’s Herceptin, just in time for the breast cancer Share XFDA approves Herceptin biosimilar as US patent expireshttps://pharmaphorum.com/news/fda-approves-herceptin-biosimilar-as-us-patent-expires/
